Table 1 qHTS assay summary statistics†

From: Profiling of the Tox21 10K compound library for agonists and antagonists of the estrogen receptor alpha signaling pathway

Assay

S/B*

CV (%)*

Z' factor

Positive Control

Positive Control AC50 (M) (±fold)

HEK293 ER-bla agonist

4.6 ± 0.6

4.7 ± 3.7

0.53 ± 0.09

17 β-Estradiol

3.14 × 10−10 (1.4)

HEK293 ER-bla antagonist

3.3 ± 0.8

5.1 ± 2.8

0.41 ± 0.10

Tamoxifen

5.01 × 10−9 (1.4)

HEK293 ER-bla viability

132.6 ± 8.2

9.4 ± 2.5

0.76 ± 0.06

Tetra n-octyl ammonium bromide

N/A

BG1 ER-luc agonist

2.5 ± 0.3

10.3 ± 4.6

0.50 ± 0.25

17 β-Estradiol

2.74 × 10−11 (2.8)

BG1 ER-luc antagonist

8.0 ± 0.9

6.5 ± 2.8

0.77 ± 0.07

Tamoxifen

7.30 × 10−8 (1.1)

BG1 ER-luc viability

6.1 ± 0.9

7.2 ± 2.1

0.81 ± 0.06

Tetra n-octyl ammonium bromide

N/A

  1. †Data presented as mean ± standard deviation.
  2. *S/B = Signal to Background, CV = Coefficient of Variance, AC50 = Concentration at 50% activity.
Back to article page